Literature DB >> 9554138

[Surgery in myopic astigmatism: arciform keratotomy and PKR versus PARK].

S Ganem1, S B Sidhoum.   

Abstract

UNLABELLED: Two surgical techniques for treatment of myopic astigmatism are compared: One technique is a combined procedure with relaxing incision and photorefractive keratectomy (RI PRK), the other one is photoreactive keratectomy done for correction of myopia and astigmatism (PARK). Fifty-nine eyes (42 patients) were operated by IR PRK. The preoperative myopia was between -1.5 and -14 D and the astigmatism between -0.75 and -6 diopters. Thirty-two eyes (20 patients) were treated with the PARK. The preoperative myopia was between -1 and -15 D and the astigmatism between -0.5 and -4. In 38 cases, relaxing incisions allowed to correct astigmatism entirely. The mean preoperative sphere of -6.8 D before PRK was 1.4 D and the spheres between -1 and -15 D. Twelve months after treatment, 26 eyes on 30 were spherical. The spherical equivalent varied between +0.75 and -1.50 D. Relaxing arciform incision presents the advantage to correct high asymmetric astigmatism without corneal thinning, as well as mixed astigmatism. At the present time, the PARK allows to correct only symmetrical myopic astigmatism.
CONCLUSION: The predictability of the results is high if the cylinder is less than 3 D and the sphere less than 6 D. Beyond this limit, there is a higher risk of regression, and haze related with the depth of photo-ablation and we prefer RI-PRK.

Entities:  

Mesh:

Year:  1997        PMID: 9554138

Source DB:  PubMed          Journal:  Bull Soc Belge Ophtalmol        ISSN: 0081-0746


  2 in total

1.  The short term effects of a single limbal relaxing incision combined with clear corneal incision.

Authors:  Dong Hyun Kim; Won Ryang Wee; Jin Hak Lee; Mee Kum Kim
Journal:  Korean J Ophthalmol       Date:  2010-04-06

2.  Effect of Limbal relaxing incisions during implantable collamer lens surgery.

Authors:  Zhen Li; Yu Han; Budan Hu; Huibin Du; Gengsheng Hao; Xiaoxi Chen
Journal:  BMC Ophthalmol       Date:  2017-05-08       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.